Dearborn Partners LLC Buys Shares of 32,039 Novartis AG $NVS

Dearborn Partners LLC purchased a new stake in Novartis AG (NYSE:NVS) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 32,039 shares of the company’s stock, valued at approximately $5,021,000.

Several other institutional investors and hedge funds have also modified their holdings of NVS. J.W. Cole Advisors Inc. raised its stake in Novartis by 0.6% during the fourth quarter. J.W. Cole Advisors Inc. now owns 10,577 shares of the company’s stock worth $1,348,000 after acquiring an additional 64 shares in the last quarter. Roundview Capital LLC boosted its stake in shares of Novartis by 2.5% in the 4th quarter. Roundview Capital LLC now owns 2,711 shares of the company’s stock valued at $374,000 after purchasing an additional 66 shares in the last quarter. CPC Advisors LLC boosted its stake in shares of Novartis by 4.6% in the 2nd quarter. CPC Advisors LLC now owns 1,516 shares of the company’s stock valued at $238,000 after purchasing an additional 66 shares in the last quarter. IMA Advisory Services Inc. grew its holdings in shares of Novartis by 10.9% during the 4th quarter. IMA Advisory Services Inc. now owns 710 shares of the company’s stock valued at $98,000 after purchasing an additional 70 shares during the last quarter. Finally, Moody National Bank Trust Division increased its position in Novartis by 4.2% during the 2nd quarter. Moody National Bank Trust Division now owns 1,802 shares of the company’s stock worth $282,000 after purchasing an additional 72 shares in the last quarter. 13.12% of the stock is currently owned by institutional investors.

Novartis Stock Performance

Shares of NVS stock opened at $154.54 on Friday. The business’s 50-day moving average price is $154.94 and its 200-day moving average price is $153.78. Novartis AG has a 12 month low of $121.57 and a 12 month high of $170.46. The firm has a market capitalization of $294.88 billion, a price-to-earnings ratio of 23.31, a PEG ratio of 2.70 and a beta of 0.45. The company has a current ratio of 0.86, a quick ratio of 0.67 and a debt-to-equity ratio of 0.89.

Novartis (NYSE:NVS) last released its quarterly earnings results on Tuesday, June 30th. The company reported $2.41 earnings per share for the quarter. Novartis had a return on equity of 38.56% and a net margin of 23.29%.The company had revenue of $14.95 billion for the quarter. Equities research analysts forecast that Novartis AG will post 8.85 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. Citigroup reissued a “buy” rating on shares of Novartis in a research note on Wednesday, July 22nd. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Novartis in a research note on Friday, July 24th. Seven investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, Novartis presently has an average rating of “Hold” and an average target price of $141.20.

About Novartis

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.